MORGAN STANLEY PLC/CALL/ASTRAZENECA ADR/92.5/0.1/20.12.24 | Market Closed - Börse Stuttgart 14:54:55 2024-06-04 EDT | ||
| 0.162 EUR | +5.19% |
|
| Current month | +21.26% | ||
| 1 month | +45.28% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
More news
| Date | Price | Change |
|---|---|---|
| 24-06-04 | 0.162 | +5.19% |
| 24-06-03 | 0.154 | +21.26% |
| 24-05-31 | 0.127 | +17.59% |
| 24-05-30 | 0.108 | +6.93% |
| 24-05-29 | 0.101 | -6.48% |
Delayed Quote Börse Stuttgart
Last update June 04, 2024 at 02:54 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | Morgan Stanley |
| WKN | MB5CV6 |
| ISIN | DE000MB5CV61 |
| Date issued | 2023-04-06 |
| Strike | 92.5 $ |
| Maturity | 2024-12-20 (199 Days) |
| Parity | 10 : 1 |
| Emission price | 0.35 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.44 € |
|---|---|
| Lowest since issue | 0.013 € |
| Spread | 0.021 € |
| Spread % | 16.15% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
158.6
USD
Average target price
172.1
USD
Spread / Average Target
+8.49%
- Stock Market
- Warrants
- Warrant
